The Beauty Health Company (NASDAQ:SKIN – Get Free Report) has been assigned a consensus recommendation of “Hold” from the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $1.3750.
A number of equities analysts recently issued reports on the stock. Weiss Ratings lowered shares of Beauty Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 23rd. Zacks Research cut shares of Beauty Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 20th. Roth Capital restated a “buy” rating and set a $2.00 target price (down from $2.50) on shares of Beauty Health in a research report on Wednesday, May 20th. Canaccord Genuity Group dropped their target price on Beauty Health from $1.50 to $1.00 and set a “hold” rating on the stock in a research report on Friday, May 1st. Finally, TD Cowen cut their price target on shares of Beauty Health from $1.00 to $0.90 and set a “hold” rating on the stock in a research report on Wednesday, August 12th.
View Our Latest Analysis on Beauty Health
Institutional Investors Weigh In On Beauty Health
Beauty Health Price Performance
Shares of NASDAQ SKIN opened at $0.63 on Friday. The stock has a market cap of $81.99 million, a P/E ratio of -2.86 and a beta of 1.07. Beauty Health has a twelve month low of $0.55 and a twelve month high of $2.69. The stock has a 50 day moving average of $0.73 and a two-hundred day moving average of $0.86. The company has a current ratio of 1.76, a quick ratio of 1.48 and a debt-to-equity ratio of 4.36.
Beauty Health (NASDAQ:SKIN – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The business had revenue of $72.11 million for the quarter, compared to analyst estimates of $74.45 million. Beauty Health had a negative net margin of 9.79% and a negative return on equity of 47.83%. On average, research analysts forecast that Beauty Health will post -0.16 earnings per share for the current year.
About Beauty Health
Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.
Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.
Read More
- Five stocks we like better than Beauty Health
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.
